Amodiaquine and chloroquine were specific NR4A2 ligands that inhibited induced inflammation in neuronal cells, enhanced NR4A2-dependent dopaminergic effects in rat cell models (Kim et al., 2015) and also in an in vivo model of Parkinson’s Disease (PD) (Kim et al., 2015) where rats are treated with 6-hydroxydopamine. This evidence concerns the gene NR4A2 and Parkinson disease.